Disc Col

Similar articles

Review Tuning tumor-specific T-cell activation: a matter of costimulation?[Trends Immunol. 2002]
Review Tuning tumor-specific T-cell activation: a matter of costimulation?
Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B. Trends Immunol. 2002 May; 23(5):240-5.
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.[Vaccine. 2004]
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.
Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, et al. Vaccine. 2004 Apr 16; 22(13-14):1700-8.
Comment on "Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade".[J Immunol. 2006]
Comment on "Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade".
O'Mahony D, Janik JE. J Immunol. 2006 May 1; 176(9):5136; author reply 5136.
Turning on tumor-fighting T-cells. Two signals are better than one when it come to developing new cancer therapies.[Biotechnology (N Y). 1993]
Turning on tumor-fighting T-cells. Two signals are better than one when it come to developing new cancer therapies.
Edgington SM. Biotechnology (N Y). 1993 Oct; 11(10):1117-9.
Review Role of the B7-CD28/CTLA-4 pathway in autoimmune disease.[Curr Dir Autoimmun. 2002]
Review Role of the B7-CD28/CTLA-4 pathway in autoimmune disease.
Chang TT, Kuchroo VK, Sharpe AH. Curr Dir Autoimmun. 2002; 5:113-30.

See reviews...See all...

Cited by 3 PubMed Central articles

Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.[Cancer Biol Ther. 2015]
Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, et al. Cancer Biol Ther. 2015; 16(5):662-70.
Hashimoto's thyroiditis pathology and risk for thyroid cancer.[Thyroid. 2014]
Hashimoto's thyroiditis pathology and risk for thyroid cancer.
Paparodis R, Imam S, Todorova-Koteva K, Staii A, Jaume JC. Thyroid. 2014 Jul; 24(7):1107-14. Epub 2014 Jun 5.
Review Trial watch: Dendritic cell-based interventions for cancer therapy.[Oncoimmunology. 2013]
Review Trial watch: Dendritic cell-based interventions for cancer therapy.
Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Oncoimmunology. 2013 Oct 1; 2(10):e25771. Epub 2013 Jul 29.

Save items

Similar articles

Cited by 3 PubMed Central articles

Related information

Recent Activity